Cystic Fibrosis: Modifier Genes

Abstract

Cystic fibrosis (CF) is a rare autosomal recessive disease that causes early death through respiratory failure. Although it is known that CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) it has been found that other genetic factors make a large contribution to the severity of lung disease as well as several other CF traits. Several large‐scale genomewide association studies have been performed for CF lung disease severity, body mass index/nutritional status, CF‐related diabetes, meconium ileus and age of onset of chronic Pseudomonas aeruginosa infection. Several genes have been identified that modulate CF disease severity. In particular, apical membrane constituents have been associated with several phenotypes including lung function, meconium ileus and age of onset of P. aeruginosa infection. The results of these studies have provided insight into the pathophysiology of CF and have identified novel therapeutic targets.

Key Concepts

  • Lung disease severity in CF, along with several other CF traits, is influenced by non‐CFTR genetic factors.
  • Genomewide association studies and linkage analysis have identified several genes associated with CF severity.
  • Meta‐analysis of several patient cohorts is required to identify reproducible findings.
  • Apical membrane constituents, in particular SLC6A14, SLC26A9 and SLC9A3, are a class of molecules associated with several CF phenotypes.
  • Exome‐wide sequencing can be used as an alternative approach to discover novel modifier genes.

Keywords: cystic fibrosis; modifier genes; genomewide association study; lung disease severity; meconium ileus

Figure 1. Apical membrane constituents that are associated with CF related traits.
close

References

Ahmed N, Corey M, Forstner G, et al. (2003) Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 52 (8): 1159–1164.

Andersen DH and Hodges RG (1946) Celiac syndrome; genetics of cystic fibrosis of the pancreas, with a consideration of etiology. American Journal of Diseases of Children 72: 62–80.

Aron Y, Polla BS, Bienvenu T, et al. (1999) HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype. American Journal of Respiratory and Critical Care Medicine 159 (5 Pt 1): 1464–1468.

Baldan A, Lo Presti AR, Belpinati F, et al. (2015) IFRD1 gene polymorphisms are associated with nasal polyposis in cystic fibrosis patients. Rhinology 53 (4): 359–364.

Bezzerri V, d'Adamo P, Rimessi A, et al. (2011) Phospholipase C‐beta3 is a key modulator of IL‐8 expression in cystic fibrosis bronchial epithelial cells. Journal of Immunology 186 (8): 4946–4958.

Blackman SM, Deering‐Brose R, McWilliams R, et al. (2006) Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 131 (4): 1030–1039.

Blackman SM, Hsu S, Vanscoy LL, et al. (2009) Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. Journal of Clinical Endocrinology and Metabolism 94 (4): 1302–1309.

Blackman SM, Commander CW, Watson C, et al. (2013) Genetic modifiers of cystic fibrosis‐related diabetes. Diabetes 62 (10): 3627–3635.

Bradford EM, Sartor MA, Gawenis LR, Clarke LL and Shull GE (2009) Reduced NHE3‐mediated Na + absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. American Journal of Physiology. Gastrointestinal and Liver Physiology 296 (4): G886–G898.

Bradley GM, Blackman SM, Watson CP, Doshi VK and Cutting GR (2012) Genetic modifiers of nutritional status in cystic fibrosis. American Journal of Clinical Nutrition 96 (6): 1299–1308.

Chang MH, Plata C, Sindic A, et al. (2009) Slc26a9 is inhibited by the R‐region of the cystic fibrosis transmembrane conductance regulator via the STAS domain. Journal of Biological Chemistry 284 (41): 28306–28318.

Chauhan B, Santiago L, Hutcheson PS, et al. (2000) Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. Journal of Allergy and Clinical Immunology 106 (4): 723–729.

Corvol H, Blackman SM, Boelle PY, et al. (2015) Genome‐wide association meta‐analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nature Communications 6: 8382.

Cutting GR (2015) Cystic fibrosis genetics: from molecular understanding to clinical application. Nature Reviews Genetics 16 (1): 45–56.

Dorfman R, Sandford A, Taylor C, et al. (2008) Complex two‐gene modulation of lung disease severity in children with cystic fibrosis. Journal of Clinical Investigation 118 (3): 1040–1049.

Dorfman R, Li W, Sun L, et al. (2009) Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results. Human Genetics 126 (6): 763–778.

Dorfman R, Taylor C, Lin F, et al. (2011) Members of Canadian Consortium for CF Genetic Studies. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis. Pediatr Pulmonol 46 (4): 385–392. DOI: 10.1002/ppul.21372

Drumm ML, Konstan MW, Schluchter MD, et al. (2005) Genetic modifiers of lung disease in cystic fibrosis. New England Journal of Medicine 353 (14): 1443–1453.

Durie PR, Soave D, Gonska T, et al. (2012) Early exocrine pancreatic damage determined by serum immunoreactive trypsinogen is a significant predictor of CF‐related diabetes at a later age. Pediatric Pulmonology 47 (S35): 408.

Emond MJ, Louie T, Emerson J, et al. (2012) Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nature Genetics 44 (8): 886–889.

Emond MJ, Louie T, Emerson J, et al. (2015) Exome sequencing of phenotypic extremes identifies CAV2 and TMC6 as interacting modifiers of chronic Pseudomonas aeruginosa infection in cystic fibrosis. PLoS Genetics 11 (6): e1005273.

Furgeri DT, Marson FA, Ribeiro AF and Bertuzzo CS (2012) Association between the IVS4G > T mutation in the TCF7L2 gene and susceptibility to diabetes in cystic fibrosis patients. BMC Research Notes 5: 561.

Green DM, Collaco JM, McDougal KE, et al. (2012) Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis. Journal of Pediatrics 161 (2): 290–295.e291.

Gu Y, Harley IT, Henderson LB, et al. (2009) Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 458 (7241): 1039–1042.

Hancock DB, Soler Artigas M, Gharib SA, et al. (2012) Genome‐wide joint meta‐analysis of SNP and SNP‐by‐smoking interaction identifies novel loci for pulmonary function. PLoS Genetics 8 (12): e1003098.

Harness‐Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D and Jain R (2014) Gender differences in outcomes of patients with cystic fibrosis. Journal of Women's Health (2002) 23 (12): 1012–1020.

Henderson LB, Doshi VK, Blackman SM, et al. (2012) Variation in MSRA modifies risk of neonatal intestinal obstruction in cystic fibrosis. PLoS Genetics 8 (3): e1002580.

Hubert D, Bienvenu T, Desmazes‐Dufeu N, et al. (1996) Genotype‐phenotype relationships in a cohort of adult cystic fibrosis patients. European Respiratory Journal 9 (11): 2207–2214.

Kerem E, Corey M, Kerem BS, et al. (1990) The relation between genotype and phenotype in cystic fibrosis‐‐analysis of the most common mutation (delta F508). New England Journal of Medicine 323 (22): 1517–1522.

Kontakioti E, Domvri K, Papakosta D and Daniilidis M (2014) HLA and asthma phenotypes/endotypes: a review. Human Immunology 75 (8): 930–939.

Li Z, Kosorok MR, Farrell PM, et al. (2005) Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293 (5): 581–588.

Li X, Hawkins GA, Ampleford EJ, et al. (2013) Genome‐wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. Journal of Allergy and Clinical Immunology 132 (2): 313–320.e315.

Li W, Soave D, Miller MR, et al. (2014) Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis‐related morbidities. Human Genetics 133 (2): 151–161.

Miller MR, Soave D, Li W, et al. (2015) Variants in solute carrier SLC26A9 modify prenatal exocrine pancreatic damage in cystic fibrosis. Journal of Pediatrics 166 (5): 1152–1157.e1156.

Moran A, Becker D, Casella SJ, et al. (2010) Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis‐related diabetes: a technical review. Diabetes Care 33 (12): 2677–2683.

Patwari P, Emilsson V, Schadt EE, et al. (2011) The arrestin domain‐containing 3 protein regulates body mass and energy expenditure. Cell Metabolism 14 (5): 671–683.

Riordan JR, Rommens JM, Kerem B, et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (4922): 1066–1073.

Rubin BK (1990) Exposure of children with cystic fibrosis to environmental tobacco smoke. New England Journal of Medicine 323 (12): 782–788.

Schechter MS, Shelton BJ, Margolis PA and Fitzsimmons SC (2001) The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. American Journal of Respiratory and Critical Care Medicine 163 (6): 1331–1337.

Siasi E and Aleyasin A (2016) Four single nucleotide polymorphisms in INSR, SLC6A14, TAS2R38, and OR2W3 genes in association with idiopathic infertility in persian men. Journal of Reproductive Medicine 61 (3–4): 145–152.

Soleimani M and Burnham CE (2001) Na+:HCO(3‐) cotransporters (NBC): cloning and characterization. Journal of Membrane Biology 183 (2): 71–84.

Sosnay PR, Siklosi KR, Van Goor F, et al. (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nature Genetics 45 (10): 1160–1167.

Steinkamp G and von der Hardt H (1994) Improvement of nutritional status and lung function after long‐term nocturnal gastrostomy feedings in cystic fibrosis. Journal of Pediatrics 124 (2): 244–249.

Sun L, Rommens JM, Corvol H, et al. (2012) Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nature Genetics 44 (5): 562–569.

Taylor C, Commander CW, Collaco JM, et al. (2011) A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies. Pediatric Pulmonology 46 (9): 857–869.

Vanscoy LL, Blackman SM, Collaco JM, et al. (2007) Heritability of lung disease severity in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 175 (10): 1036–1043.

Wagenaar GT, Sengers RM, Laghmani el H, et al. (2014) Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia‐induced lung and heart injury at a low dose in newborn rats. American Journal of Physiology. Lung Cellular and Molecular Physiology 307 (3): L261–L272.

Wilschanski M, Zielenski J, Markiewicz D, et al. (1995) Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. Journal of Pediatrics 127 (5): 705–710.

Wright FA, Strug LJ, Doshi VK, et al. (2011) Genome‐wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nature Genetics 43 (6): 539–546.

Zaas DW, Swan ZD, Brown BJ, et al. (2009) Counteracting signaling activities in lipid rafts associated with the invasion of lung epithelial cells by Pseudomonas aeruginosa. Journal of Biological Chemistry 284 (15): 9955–9964.

Further Reading

Brennan ML and Schrijver I (2016) Cystic fibrosis: a review of associated phenotypes, use of molecular diagnostic approaches, genetic characteristics, progress, and dilemmas. Journal of Molecular Diagnostics 18 (1): 3–14.

Chang EH and Zabner J (2015) Precision genomic medicine in cystic fibrosis. Clinical and Translational Science 8 (5): 606–610.

Corvol H, Thompson KE, Tabary O, le Rouzic P and Guillot L (2016) Translating the genetics of cystic fibrosis to personalized medicine. Translational Research 168: 40–49.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Saferali, Aabida, Turvey, Stuart E, and Sandford, Andrew J(Sep 2016) Cystic Fibrosis: Modifier Genes. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0020233]